* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
0.5% proprietary stabilizer
0.05% sodium azide
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Specific Information
MA5-17127 targets MPL in FACS and WB applications and shows reactivity with Human samples.
The MA5-17127 immunogen is purified recombinant fragment of human MPL expressed in E. Coli.
MA5-17127 detects MPL which has a predicted molecular weight of approximately 71.2kDa.
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.
c-Mpl / CD110 Antibody (MA5-17127) in WB CD110-MPL_Antibody_MA5-17127_Westernblot1-1252013.jpg
Western Blot with anti-c-Mpl / CD110 Monoclonal Antibody [1H2] (MA5-17127)